Our findings suggest that genetic variation in these VDR binding sites, upregulated in response to treatment with vitamin D and relevant to colorectal carcinogenesis and inflammatory bowel diseases, may be associated with CRC risk. The gene discussed is VDR; the disease is inflammatory bowel disease.